TRANSCODE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was -1.93M shares.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 0.00 shares.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.10K shares, a 2259.55% increase from fiscal 2023.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 89.00 shares, a 94.83% decline from fiscal 2022.
- TRANSCODE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.72K shares, a 95.27% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 0.00 shares 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | 0.00 shares 10-K · filed 2026-04-15 | |||||
| 2024-12-31 | -1.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -1.93M shares derived: sum of 2 quarters · filed 2026-04-15 | 2.10K shares derived: sum of 3 quarters · filed 2026-04-15 | 2.10K shares 10-K · filed 2026-04-15 | 58.50K shares 10-K · filed 2025-04-15 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 1.93M shares derived: sum of 2 quarters · filed 2024-11-14 | 1.93M shares 10-Q · filed 2024-11-14 | 1.81M shares derived: sum of 4 quarters · filed 2025-04-15 | ||
| 2024-06-30 | 1.93M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.93M shares 10-Q · filed 2024-08-14 | 1.81M shares derived: sum of 3 quarters · filed 2025-04-15 | 1.81M shares derived: sum of 4 quarters · filed 2025-04-15 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | -116.34K shares derived: sum of 2 quarters · filed 2025-04-15 | -116.34K shares derived: sum of 3 quarters · filed 2025-04-15 | |||
| 2023-12-31 | -116.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -116.34K shares derived: sum of 2 quarters · filed 2025-04-15 | 89.00 shares 10-K · filed 2025-04-15 | 2.91K shares 10-K · filed 2024-04-01 | ||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 116.42K shares 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | 116.42K shares 10-Q · filed 2023-08-14 | |||||
| 2022-12-31 | -479.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -479.78K shares derived: sum of 2 quarters · filed 2024-04-01 | -451.28K shares derived: sum of 3 quarters · filed 2024-04-01 | 1.72K shares 10-K · filed 2024-04-01 | 1.38M shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 28.50K shares derived: sum of 2 quarters · filed 2022-11-14 | 481.50K shares 10-Q · filed 2022-11-14 | 481.50K shares derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2022-06-30 | 28.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 481.50K shares 10-Q · filed 2022-08-15 | 481.50K shares derived: sum of 3 quarters · filed 2023-03-31 | 481.50K shares derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2022-03-31 | 453.00K shares 10-Q · filed 2022-05-16 | 453.00K shares derived: sum of 2 quarters · filed 2023-03-31 | 453.00K shares derived: sum of 3 quarters · filed 2023-03-31 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-31 | 36.39K shares 10-K · filed 2023-03-31 | |||
| 2021-09-30 | 0.00 shares 10-Q · filed 2021-11-15 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 36.39K shares 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | 36.39K shares 10-Q · filed 2021-08-23 | |||||
| 2020-12-31 | 1.76M shares 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |